| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CCR2 (specifically the CCR2b isoform).
|
|---|---|
| ln Vitro |
CCR2 antagonist 4 binds to CCR2 primarily because of Ile263 and Thr292 in CCR2. The binding of protonated CCR2 antagonist 4 hydrochloride and CCL2 is greatly aided by residue Glu291 in TM7, a highly conserved residue seen in numerous CC chemokine receptors. Additionally, the CCR2 antagonist 4 hydrochloride exhibits substantial interactions with His121 on TM3 and Ile263 on TM6 [2].
CCR2 antagonist 4 HCl is a potent CCR2 antagonist, with an IC₅₀ of 180 nM for CCR2b. It potently inhibits MCP-1 (CCL2)-induced chemotaxis, a key functional readout of CCR2 activity, with an IC₅₀ of 24 nM. The binding is driven by specific interactions with residues such as Ile263 and Thr292 in CCR2. |
| ln Vivo |
Vp-TSL specifically targets endothelial VCAM-1 in the aortic plaque and CCR2 antagonist 4 hydrochloride in ApoE-deficient animals, thereby lowering adhesion/infiltration of a mouse monocyte/macrophage line (RAW 264.7) into the aortic plaque. vessels[3].
In vivo, CCR2 antagonist 4 HCl has been studied in ApoE-deficient animal models of atherosclerosis. When formulated in VCAM-1-targeted liposomes (Vp-TSL), it reduces the adhesion and infiltration of monocytes/macrophages into aortic plaques. This demonstrates its potential for treating inflammatory diseases. |
| Enzyme Assay |
In vitro activity is assessed using radioligand binding assays to measure affinity for CCR2, and functional assays to measure inhibition of MCP-1-induced chemotaxis. In chemotaxis assays, cells expressing CCR2 are placed in a chamber, and the compound's ability to block migration towards MCP-1 is measured.
|
| Cell Assay |
In vitro cellular assays typically use cell lines (e.g., THP-1 or primary monocytes) that endogenously express CCR2. The compound's ability to inhibit MCP-1-induced calcium flux or cell migration is measured.
|
| Animal Protocol |
In vivo efficacy is studied in disease models such as atherosclerosis in ApoE-deficient mice. The compound, often formulated in targeted liposomes, is administered, and its effect on monocyte infiltration and plaque formation is assessed.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data is not provided in the references. However, the hydrochloride salt form is used to enhance stability and solubility. It is formulated for research use.
|
| Toxicity/Toxicokinetics |
Specific toxicological data is not provided. As a research compound, it is for laboratory use only.
|
| References |
|
| Additional Infomation |
CCR2 antagonist 4 HCl is a research tool for studying CCR2 biology. It is not approved for clinical use.
|
| Molecular Formula |
C₂₁H₂₂CL₂F₃N₃O₂
|
|---|---|
| Molecular Weight |
476.32
|
| Exact Mass |
475.104
|
| CAS # |
1313730-14-1
|
| Related CAS # |
CCR2 antagonist 4;226226-39-7
|
| PubChem CID |
56972239
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
597
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CC3=CC=C(C=C3)Cl.Cl
|
| InChi Key |
PGUQBBISBKGQDC-GMUIIQOCSA-N
|
| InChi Code |
InChI=1S/C21H21ClF3N3O2.ClH/c22-17-6-4-14(5-7-17)12-28-9-8-18(13-28)27-19(29)11-26-20(30)15-2-1-3-16(10-15)21(23,24)25;/h1-7,10,18H,8-9,11-13H2,(H,26,30)(H,27,29);1H/t18-;/m1./s1
|
| Chemical Name |
N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]pyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide;hydrochloride
|
| Synonyms |
CCR2 antagonist 4 HCl CCR2 antagonist 4 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~524.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0994 mL | 10.4971 mL | 20.9943 mL | |
| 5 mM | 0.4199 mL | 2.0994 mL | 4.1989 mL | |
| 10 mM | 0.2099 mL | 1.0497 mL | 2.0994 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
